These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 31836564)

  • 1. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
    Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
    J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
    Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
    Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
    Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
    N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
    Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
    PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
    Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
    Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.
    Farberg AS; Portela D; Sharma D; Kheterpal M
    Am J Clin Dermatol; 2024 Sep; 25(5):779-794. PubMed ID: 38896403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
    Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
    J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
    Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
    J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).
    Nguyen A; Xie P; Litvinov IV; Lefrançois P
    Am J Clin Dermatol; 2023 May; 24(3):359-374. PubMed ID: 36795228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
    JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.